(a) Time course for the urinary protein/urinary creatinine ratio. Proteinuria was not different in both groups until day 3, but became significantly higher on days 8 and 12 in dibenzazepine (DBZ)-treated LMB2 mice. (b) PEC scores were significantly reduced in DBZ-treated LMB2 mice; the frequency and severity of PEC lesion were lower in the DBZ-treated group (0.33±0.03 vs. 0.19±0.02; P = 0.028, LMB2 vs. LMB2+DBZ mice). (c) The numbers of WT1-positive cells per glomerulus were not significantly different between these groups (2.87±0.19 vs. 2.69±0.19 cells per glomerulus; P = 0.54). A low-magnification view of the renal cortex of a nontreated LMB2 mouse showed a few urinary casts by (d) periodic acid–Schiff (PAS) staining, whereas far more abundant urinary casts were observed in (e) DBZ-treated LMB2 mice. (f) Planimetry of urinary casts in the renal cortex revealed significantly more protein casts in the DBZ-treated LMB2 mice (8.01±0.81 vs. 28.24±4.17%; P<0.001, LMB2 vs. LMB2+DBZ mice). In each group, n = 5; *P<0.05 and **P<0.001 for LMB2 vs. LMB2+DBZ mice. NS, not significant. Bars = 150 μm.